نتائج البحث - Amitkumar Mehta

  • يعرض 1 - 20 نتائج من 20
تنقيح النتائج
  1. 1
    Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin

    Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin حسب Uma Borate, Amitkumar Mehta, Vishnu Reddy, Michaela Tsai, Neil C. Josephson, Ian D. Schnadig

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

    Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma حسب Alex F. Herrera, André Goy, Amitkumar Mehta, Radhakrishnan Ramchandren, John M. Pagel, Jakub Svoboda, Shanhong Guan, John S. Hill, Kevin Kwei, Emily A. Liu, Tycel Phillips

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

    Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Mal... حسب Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu‐Waye Chu, Jae H. Park

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

    Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study حسب Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, Amitkumar Mehta, Gilles Salles, Corinne Haïoun, Javier Muñoz, Andy I. Chen, Kathryn S. Kolibaba, Dan Lü, Mark Yan, Elicia Penuel, Jamie Hirata, Calvin Lee, Jeff P. Sharman

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up

    Magrolimab Plus Rituximab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Phase 1/2 Trial 3-Year Follow-up حسب Amitkumar Mehta, Leslie Popplewell, Graham P. Collins, Sonali M. Smith, Ian W. Flinn, Nancy L. Bartlett, Nilanjan Ghosh, Gal Hacohen-Kleiman, Yanan Huo, Linda Su-Feher, Camille Renard, Ranjana H. Advani, Mark Roschewski

    منشور في 2024
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

    Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001 حسب Maria Lia Palomba, Leo I. Gordon, Tanya Siddiqi, Jeremy S. Abramson, Manali Kamdar, Matthew A. Lunning, David G. Maloney, Charalambos Andreadis, Jon Arnason, Nilanjan Ghosh, Amitkumar Mehta, Scott R. Solomon, Thalia A. Farazi, Jacob Garcia, Christine Dehner, K. OGASAWARA, Jie Gao, Michael Wang

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

    Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study حسب Adam J. Olszewski, Tycel Phillips, Marc Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason R. Westin, Izidore S. Lossos, Javier Muñoz, Jason Sit, Michael C. Wei, Annie Yang, Vivian Chen, Enkhtsetseg Purev, Donald L. Yee, Ulrich Jaeger

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

    Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas حسب Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, D. Li, Yeonhee Kim, Tanya Siddiqi

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma حسب Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Domènech, Amitkumar Mehta, Andres Forero‐Torres, Ramón García‐Sánz, Philippe Armand, Sumana Devata, Antonia Rodríguez Izquierdo, Izidore S. Lossos, Craig B. Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, András Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

    Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies حسب Gerald S. Falchook, Seth Rosen, Patricia LoRusso, Justin M. Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan D. Cassaday, Wael A. Harb, Julio A. Peguero, David C. Smith, Sarina A. Piha‐Paul, Russ Szmulewitz, Marcus Smith Noel, Swamy Yeleswaram, Phillip Liu, Julie Switzky, Gongfu Zhou, Fred Zheng, Amitkumar Mehta

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

    Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial حسب Lihua E. Budde, Adam J. Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D. Smith, Kathleen A. Dorritie, Ting Jia, Song Pham, Ling‐Yuh Huw, Jing Jing, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Julio C. Chávez

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

    PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD حسب Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani, Philippe Armand, Mary E.D. Flowers, Reid W. Merryman, Manali Kamdar, Abraham S. Kanate, Ayman Saad, Amitkumar Mehta, Siddhartha Ganguly, Timothy S. Fenske, Parameswaran Hari, Robert Lowsky, Leslie A. Andritsos, Madan Jagasia, Asad Bashey, Stacey Brown, Veronika Bachanová, Deborah M. Stephens, Shin Mineishi, Ryotaro Nakamura, Yi‐Bin Chen, Bruce R. Blazar, Jonathan A. Gutman, Steven M. Devine

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies

    Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies حسب Luciano J. Costa, Kami J. Maddocks, Narendranath Epperla, Nishitha Reddy, Reem Karmali, Elvira Umyarova, Veronika Bachanová, Cristiana A Costa, Martha Glenn, Julio C. Chávez, Oscar Calzada, Frederick Lansigan, Hossain Nasheed, Stefan K. Barta, Zheng Zhou, Michael Jaglal, Saurabh Chhabra, Francisco J. Hernandez‐Ilizaliturri, Ana C. Xavier, Amitkumar Mehta, Deniz Peker, Andreas Forero‐Torres, Zeina Al‐Mansour, Andrew M. Evens, Jonathon B. Cohen, Christopher R. Flowers, Timothy S. Fenske, Mehdi Hamadani

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology

    Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology حسب Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin L. Ard, Robert A. Baiocchi, Stefan K. Barta, Evie H. Carchman, Adam L. Cohen, Neel K. Gupta, Kimberly L. Johung, Ann H. Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova‐Rusher, Amitkumar Mehta, Manoj Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank J. Palella, Lee Ratner, Stacey A. Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, Deborah A. Freedman-Cass

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    AIDS-Related Kaposi Sarcoma, Version 2.2019

    AIDS-Related Kaposi Sarcoma, Version 2.2019 حسب Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin L. Ard, Robert A. Baiocchi, Stefan K. Barta, Evie H. Carchman, Adam K. Cohen, Oxana Crysler, Neel K. Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann H. Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey A. Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, Deborah A. Freedman-Cass

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018

    NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018 حسب Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta, Michael Y. Choi, Mark W. Clemens, Ahmet Doǧan, John P. Greer, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric D. Jacobsen, Deepa Jagadeesh, Youn H. Kim, Matthew A. Lunning, Amitkumar Mehta, Neha Mehta–Shah, Y. Oki, Elise A. Olsen, Barbara Pro, Saurabh Rajguru, Satish Shanbhag, Andrei R. Shustov, Lubomir Sokol, Pallawi Torka, Ryan A. Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

    NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019 حسب Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie Chang, Julio C. Chávez, Beth Christian, Luis Fayad, Martha Glenn, Thomas M. Habermann, Nancy L. Harris, Francisco J. Hernandez‐Ilizaliturri, Mark Kaminski, Chris R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, Hema Sundar

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020

    NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020 حسب Neha Mehta–Shah, Sarah McCue Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta, Mark W. Clemens, Ahmet Doǧan, Kristopher Fisher, Aaron M. Goodman, Gaurav Goyal, Joan Guitart, Ahmad Halwani, Bradley M. Haverkos, Richard T. Hoppe, Eric D. Jacobsen, Deepa Jagadeesh, Matthew A. Lunning, Amitkumar Mehta, Elise A. Olsen, Barbara Pro, Saurabh Rajguru, Satish Shanbhag, Aaron C. Shaver, Andrei R. Shustov, Lubomir Sokol, Pallawi Torka, Carlos A. Torres‐Cabala, Ryan A. Wilcox, Basem M. William, Jasmine Zain, Mary A. Dwyer, Hema Sundar, Youn H. Kim

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

    Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models حسب Samuel Y. Ng, Noriaki Yoshida, Amanda L. Christie, Mahmoud Ghandi, Neekesh V. Dharia, Joshua M. Dempster, Mark A. Murakami, Kay Shigemori, Sara Morrow, Alexandria Van Scoyk, Nicolas A. Cordero, Kristen E. Stevenson, Mäneka Puligandla, Brian J. Haas, Christopher Lo, Robin M. Meyers, Galen F. Gao, Andrew D. Cherniack, Abner Louissaint, Valentina Nardi, Aaron R. Thorner, Henry W. Long, Xintao Qiu, Elizabeth A. Morgan, David M. Dorfman, Danilo Fiore, Julie K. Jang, Alan L. Epstein, Ahmet Doǧan, Yanming Zhang, Steven M. Horwitz, Eric D. Jacobsen, Solimar Santiago, Jian-Guo Ren, Vincent Guerlavais, D. Allen Annis, Manuel Aivado, Mansoor N. Saleh, Amitkumar Mehta, Aviad Tsherniak, David E. Root, Francisca Vázquez, William C. Hahn, Giorgio Inghirami, Jon C. Aster, David M. Weinstock, Raphael Koch

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era

    Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era حسب James N. Gerson, Elizabeth A. Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani, Shaoying Li, L. Jeffrey Medeiros, Michael I. Wang, Jonathon B. Cohen, Oscar Calzada, Michael C. Churnetski, Brian T. Hill, Yazeed Sawalha, Francisco J. Hernandez‐Ilizaliturri, Shalin Kothari, Julie M. Vose, Martin Bast, Timothy S. Fenske, Swapna Narayana Rao Gari, Kami J. Maddocks, David A. Bond, Veronika Bachanová, Bhaskar Kolla, Julio C. Chávez, Bijal Shah, Frederick Lansigan, Timothy F. Burns, Alexandra M. Donovan, Nina D. Wagner‐Johnston, Marcus Messmer, Amitkumar Mehta, Jennifer K. Anderson, Nishitha Reddy, Alexandra E. Kovach, Daniel J. Landsburg, Martha Glenn, David J. Inwards, Reem Karmali, Jason Kaplan, Paolo F. Caimi, Saurabh Rajguru, Andrew M. Evens, Andreas K. Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer E. Amengual, Jennifer Kimberly Lue, Catherine Diefenbach, Richard I. Fisher, Stefan K. Barta

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: